AMLM22/D4: The International AML Platform Consortium (IAPC) trial – is a randomised, 2-arm trial that will investigate the efficacy of oral Azacitidine combined with an allogeneic dendritic cell vaccine vididencel, compared with oral Azacitidine alone, in maintaining or inducing negativity for measurable residual disease (MRD) in AML patients in first complete remission (CR1) following intensive chemotherapy.

Start Date30 Jun 2025

Sponsor / Collaborator

The Australian Leukaemia & Lymphoma Group

[+1]

NCT06454409 / Not yet recruitingPhase 1IIT

A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase Ib trial tests the safety, side effects, best dose and effectiveness of regorafenib in combination with venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Regorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Giving regorafenib in combination with venetoclax and azacitidine may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.

Start Date20 Mar 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06317649 / RecruitingPhase 2IIT

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Start Date03 Mar 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Azacitidine

100 Translational Medicine associated with Azacitidine

100 Patents (Medical) associated with Azacitidine

5,907

Literatures (Medical) associated with Azacitidine

05 Jul 2106·Oncotarget

Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells

Article

Author: Barash, Itamar ; Reichenstein, Moshe ; Kisliouk, Tatiana ; Kfir, Shenhav ; Rauner, Gat

Deregulated STAT5 activity in the mammary gland causes parity-dependent tumorigenesis. Epithelial cell cultures transfected with constitutively active STAT5 express higher levels of the histone H2AX than their non-transfected counterparts. Higher H2AX expression may be involved in tumorigenesis. Here, we aimed to link high STAT5 activity to H2AX-GFP expression by looking for distinct types of mammary cells that express these proteins. In vitro and in transgenic mice, only 0.2 and 0.02%, respectively, of the cells expressed the H2AX-GFP hybrid gene. Its expression correlated with that of the endogenous H2AX gene, suggesting that detectable H2AX-GFP expression marks high levels of H2AX transcript. Methylation of the H2AX promoter characterized non-GFP-expressing H2AX-GFP cells and was inversely correlated with promoter activity. Administration of 5-azacytidine increased H2AX promoter activity in an activated STAT5-dependent manner. In transgenic mice, H2AX-GFP expression peaked at pregnancy. The number of H2AX-GFP-expressing cells and GFP expression decreased in a Stat5a-null background and increased in mice expressing the hyperactivated STAT5. Importantly, H2AX-GFP activity was allocated to basal mammary cells lacking stem-cell properties, whereas STAT5 hyperactivity was detected in the adjacent luminal cells. Knockdown of RANKL by siRNA suggested its involvement in signaling between the two layers. These results suggest paracrine activation of H2AX via promoter demethylation in specific populations of basal mammary cells that is induced by a signal from neighboring luminal cells with hyper STAT5 activity. This pathway provides an alternative route for the luminally confined STAT5 to affect basal mammary cell activity.

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Article

Author: Yan, Qiong ; Cui, Jingying ; Yuan, Guolin ; Chen, Xuexing ; Li, Chunfang

OBJECTIVES:

The combination of Venetoclax (VEN) and Azacitidine (AZA) increases survival outcomes and yields excellent responses in patients with acute myeloid leukemia (AML). However, dose reduction (or discontinuation) is commonly encountered due to therapy-related toxicity. Thus, this study aimed to investigate the efficiency and safety of a lower dosage of venetoclax for the treatment of AML.

METHODS:

This observational study analyzed the characteristics and outcomes of newly diagnosed AML patients who received 100 mg VEN combined with AZA for 14 days at our institution.

RESULTS:

A total of 36 patients were enrolled, and the median age at diagnosis was 64 years. After a median follow-up of 15 (range 4-29) months, the median overall survival (OS) and progression-free survival (PFS) for the whole cohort were 17 (4-29) months and 12 (1-28) months, respectively. Meanwhile, the overall response rate (ORR) was 69.4%, and the CRc rate was 66.7% in the whole cohort. Subgroup analysis revealed that NPM1 mutations and FAB-M5 subtype were associated with higher response rates, whereas the adverse ELN risk group was predictive of an inferior response. Moreover, ASXL1, NPM1, and IDH1/2 mutations negatively impacted PFS.

DISCUSSION:

Our study optimized the administration of venetoclax plus azacytidine for the treatment of AML patients. Response rates were favorable, with median survival in agreement with the findings of earlier reports, offering valuable insights for optimizing VEN-based regimens.

CONCLUSION:

In summary, the VEN combination regimen is effective for the treatment of newly diagnosed AML patients in the real world despite VEN dose reductions .

31 Dec 2024·Hematology (Amsterdam, Netherlands)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia

Review

Author: Chen, Lin ; Mi, Ruihua ; Wei, Xudong ; Wang, Lin ; Cui, Yu ; Li, Dongbei

OBJECTIVES:

Acute undifferentiated leukemia (AUL) is a clinical rare leukemia with an overall poor prognosis. Currently, there are no well-established treatment guidelines for AUL, further exploration of optimal treatment options is now required.

METHODS:

We report an AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital and we present the clinical features. In addition, we conducted a literature review.

RESULTS:

The "VA" scheme combines agents Venetoclax and Azacitidine that have synergistic therapeutic effect with a tolerable safety profile. There is no previous report of the "VA" scheme employed in AUL treatment. An AUL patient who was complicated by a NRAS mutation and del5q was admitted to our hospital. The "VA" scheme was administrated, and complete remission (CR) was achieved at the end of the first cycle. The patient then underwent HLA-identical sibling allogeneic hematopoietic stem cell transplantation.

DISCUSSION:

The "VA" scheme has been extensively used in AML treatment, but its application in AUL treatment has not yet been reported. This study is the first to report an AUL patient treated with the "VA" scheme and achieved CR. Our result preliminarily suggested the effectiveness and safety of the "VA" scheme in AUL treatment, but validation is required in more clinical samples. The "VA" scheme provides a new treatment option for AUL patients and deserves further clinical promotion.

542

News (Medical) associated with Azacitidine

17 Jun 2024

·www.globenewswire.com

Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who previously failed or relapsed after hypomethylating agent therapy Median overall survival was 18.5 months (95% CI, range 6.1-30.9 months) with median event-free survival of 7.2 months (95% CI, range 6.3-8.2 months) HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that investigators at the University of Texas MD Anderson Cancer Center’s Leukemia department presented clinical data on seclidemstat in patients with MDS and CMML at the 2024 European Hematology Association (EHA) Hybrid Congress. The meeting was held in Madrid and virtually from June 13-16, 2024. Seclidemstat is a novel oral, reversible, targeted LSD1 inhibitor. The poster was presented by Guillermo Montalban-Bravo, M.D. on June 14th, and is available on Salarius’ website, in the Investors, Events and Presentations section here. The objective of this investigator-initiated Phase 1/2 dose-escalation study is to evaluate the safety, tolerability, maximum tolerated dose and overall response of seclidemstat in combination with azacitidine in adult patients with higher-risk MDS or CMML who previously failed or relapsed after hypomethylating agent therapy. As of May 2024, 16 patients were enrolled in this study with 14 patients evaluable for efficacy. As presented at EHA, of the 14 evaluable patients for efficacy, 6 (43%) had an objective response including 1 complete response, 3 marrow complete responses, 1 marrow complete response plus hematological improvement and 1 hematologic improvement. The median overall survival was 18.5 months (95% CI, range 6.1-30.9 months), median event-free survival was 7.2 months (95% CI, range 6.3-8.2 months) and median follow-up time was 18.9 months (95% CI, range 0-48 months) from treatment initiation. As reported, overall survival after failing therapy with hypomethylating agents typically is 4-6 months. 15 patients were evaluable for toxicity, with a dose-limiting toxicity observed in 1 patient in the 750mg BID cohort. Per protocol, the cohort was expanded to 3 additional patients. Based upon reported data, Salarius believes adverse events observed were manageable. The Phase 1 dose-escalation portion of this study will evaluate up to six dose levels of seclidemstat. Cohort 5 (dose level 750mg BID seclidemstat in combination with azacitidine) is currently enrolling and cohort 6, the final cohort, will receive 900mg BID seclidemstat in combination with azacitidine. The maximum tolerated dose, which will inform the Phase 2 portion of the study, has not yet been reached. “We are encouraged by these promising results at this early stage of the study when seclidemstat is combined with azacitidine at doses below what we believe will be the recommended Phase 2 dose,” said William McVicar, Ph.D., Chairman of the Salarius Pharmaceuticals Board of Directors. “Patients who have failed prior treatments including hypomethylating agents have a poor prognosis and are in desperate need of new treatment options. With a 43% overall response rate, median overall survival of 18.5 months and median event-free survival of 7.2 months, we agree with the investigators that these results show promising early signs of activity in a high-risk MDS and CMML treatment failure population.” About Salarius PharmaceuticalsSalarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, its lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of non-Hodgkin’s lymphoma. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn. In August 2023 Salarius announced a comprehensive review of strategic alternatives focused on maximizing shareholder value. While these efforts are ongoing, the Company continues to support its clinical programs, as appropriate, which includes the work being performed by the investigators at MD Anderson Cancer Center. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “believe,” “developing,” “expect,” “may,” “progress,” “potential,” “could,” “look forward,” “encouraging,” “might,” “should,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: Salarius’ expectations regarding the exploration of strategic alternatives, opportunities to extend Salarius’ resources, the Company’s expected cash runway, the Company’s expectations that the cost-savings measures will support the generation of additional data from the ongoing Phase 1/2 clinical trials in hematologic cancers and Ewing sarcoma; the future of the Company’s operations and product candidates; the future of the Company’s preclinical studies and clinical trials and development activities; the advantages of protein degraders including the value of SP-3164 as a cancer treatment; the value of seclidemstat as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in these forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the risk that exploration of strategic alternatives may not result in any definitive transaction or enhance stockholder value and may create a distraction or uncertainty that may adversely affect our operating results, business, or investor perceptions; the potential for the Company to seek other alternatives for restructuring and resolving its liabilities, including bankruptcy proceedings, a dissolution and orderly wind-down of operations; expectations regarding future costs and expenses; our product candidates being in early stages of development; the uncertainty about the paths of our programs and our ability to evaluate and identify a path forward for those programs, particularly given the constraints we have as a small company with limited financial, personnel and other operating resources (including with respect to the allocation of our limited capital and the sufficiency of our capital in the near term for any path we do select); Salarius’ ability to continue as a going concern; the sufficiency of Salarius’ capital resources; availability of suitable third parties with which to conduct contemplated strategic transactions; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed successfully and on attractive terms or at all; whether our cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital requirements; changes in the Company’s operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis; the risks associated with reductions in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization; the risk of not having a full-time chief executive officer; future clinical trial results and the impact of such results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the competitive landscape and other industry-related risks; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. CONTACT: LHA Investor RelationsKim Sutton Golodetz kgolodetz@lhai.com212-838-3777

Clinical ResultPhase 1Phase 2

17 Jun 2024

·www.biospace.com

Gilead’s Magrolimab Ineffective, Linked to Increase Risk of Death in MDS Patients

Pictured: Signage outside Gilead's headquarters in California/iStock, Sundry Photography Gilead Sciences on Friday unveiled its final analysis of the Phase III ENHANCE study, providing more details surrounding the troubled development of its blood cancer therapy magrolimab. In the late-stage trial—which compared magrolimab against placebo in nearly 540 higher-risk myelodysplastic syndromes (HR-MDS) patients who were also receiving standard-of-care azacitidine—Gilead’s antibody resulted in an approximately 20% higher risk of death versus placebo, though this effect was not statistically significant. Overall survival in the magrolimab arm was also shorter by approximately three months. Magrolimab’s objective response rate was 53.7%, which was lower than the observed rate of 58.7% in placebo comparators. Median progression-free survival was also slightly shorter in magrolimab-treated patients. In addition to missing its efficacy endpoints, magrolimab was associated with excess side effects. Grade 3 or higher treatment-emergent adverse events arose in 92.8% of treated patients, compared to 79.2% of those in the placebo group. Overall, 84.8% of adverse events were found to be related to magrolimab, and 24% of patients had to discontinue the antibody due to toxicities. Gilead presented these data at last week’s 2024 Hybrid Congress of the European Hematology Association. According to ENHANCE’s abstract, its results are limited by several confounding factors including the imbalance in patients eligible for transplant between groups, as well as a partial clinical hold during its enrollment. Nevertheless, these findings “highlight challenges of developing anti-CD47 therapies and other new treatments” for HR-MDS, the abstract states. Gilead gained the rights to magrolimab from its $4.9 billion acquisition of California-based biotech Forty Seven in 2020. The monoclonal antibody, which at the time was touted to have first-in-class potential, works by targeting and binding to the CD47 protein, which is commonly highly expressed in cancer cells. Through this mechanism of action, magrolimab is designed to boost the anti-cancer activity of the immune system and enable its phagocytic players to eliminate cancer cells. However, magrolimab’s development has run into several safety and efficacy hurdles over the years. In January 2022, the FDA placed a partial clinical hold on studies evaluating the combination of magrolimab and azacitidine after unexpected safety signals. At the time, Gilead attributed the hold to an imbalance in serious adverse reactions. Soon after, Gilead revealed that the hold had extended to two other magrolimab studies, which did not pair it with azacitidine. The FDA lifted all clinical holds in April 2022 following a comprehensive review of its safety data. In July 2023, Gilead announced that it had discontinued ENHANCE after a planned interim analysis satisfied the criteria for futility. In its first-quarter 2024 business report, Gilead revealed that it had terminated all of its studies of magrolimab. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Phase 3Clinical ResultAcquisition

16 Jun 2024

·firstwordpharma.com

EHA24: New data detail demise of Gilead's magrolimab in high-risk MDS

According to Phase III study details presented at the European Hematology Association (EHA) meeting, Gilead Sciences' $4.9-billion CD47 bet magrolimab was both ineffective and associated with a higher risk of death among patients with untreated higher-risk myelodysplastic syndrome (MDS).The company axed the drug's development in haematologic cancers earlier this year after three clinical trials in MDS and acute myeloid leukaemia (AML) had revealed a mortality signal. That was followed soon after by Gilead pausing work on the anti-CD47 antibody in solid tumours as well. The investigational anti-CD47 immunotherapy, which Gilead acquired through its 2020 takeout of Forty Seven in 2020, was officially scrapped all together at the end of April.Results from the 539-patient ENHANCE study presented at EHA showed that when combined with standard-of-care azacitidine, magrolimab failed on the study's primary endpoints of overall survival (OS) and complete remission (CR) rate compared to placebo plus azacitidine in previously untreated patients with higher-risk MDS.At the final analysis, best response of CR was lower at 21.3% for patients receiving magrolimab, compared to 23.6% for the placebo group. Median CR duration was also lower at 10.9 months and 11.1 months, respectively. The magrolimab regimen was associated with a 20% increased risk of death, although the difference between the arms was not statistically significant. Median OS was 15.9 months with the magrolimab plus azacitidine versus 18.6 months for controls."Confounding factors, such as imbalance in patients eligible for transplant and a partial clinical hold during enrollment, may limit data interpretation," researchers said in the ENHANCE study's abstract.Safety was also a concern. The magrolimab combination arm saw a higher rate of Grade ≥3 and treatment-related side effects compared to azacitidine alone, including neutropenia (44.5% vs 40.9%), anaemia (42.6% vs 21.2%), thrombocytopenia (40.3% vs 33.3%), and febrile neutropenia (22.8% vs 18.9%). In 2022, an urgent safety measure was introduced to maintain a haemoglobin level of at least 9 g/dL within 24 hours before the first two doses of magrolimab or placebo. While the measure improved tolerability of Gilead's drug, the study was ultimately stopped early due to futility at the interim analysis.

Phase 3ImmunotherapyClinical ResultPhase 2Clinical Trial Failure

100 Deals associated with Azacitidine

External Link

KEGG	Wiki	ATC	Drug Bank
D03021	Azacitidine	L01BC07	DB00928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Juvenile Myelomonocytic Leukemia	US	Bristol Myers Squibb Co.	20 May 2022
Philadelphia chromosome positive chronic myelogenous leukemia	CN	Celgene Europe Ltd.	24 Apr 2017
High Risk Myelodysplastic Syndrome	AU	Celgene Pty Ltd.	30 Nov 2009
Acute Myeloid Leukemia	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Acute Myeloid Leukemia	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Chronic Myelomonocytic Leukemia	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	EU	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	IS	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	LI	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myeloproliferative Disorders	NO	Bristol-Myers Squibb Pharma EEIG	17 Dec 2008
Myelodysplastic Syndromes	US	Bristol Myers Squibb Co.	19 May 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunoblastic Lymphadenopathy	Phase 3	JP	Celgene Corp.	06 Nov 2018
Thrombocytopenia	Phase 3	US	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	AU	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	BE	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	BR	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	CA	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	CZ	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	DK	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	FI	Celgene Corp.	26 Apr 2013
Thrombocytopenia	Phase 3	FR	Celgene Corp.	26 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01757535 (QUAZAR AML-001, ASCO2024) Manual	Phase 3	Acute Myeloid Leukemia with Myelodysplasia-Related Changes Maintenance	101	Oral-AZA 300 mg	oqbdkaphny(yqogbegnvr) = jchtxxrobm jnwmadiqom (anjqkyhpte, 14.59-31.97) View more	Positive	24 May 2024
NCT01757535 (QUAZAR AML-001, ASCO2024) Manual	Phase 3		101	Placebo	oqbdkaphny(yqogbegnvr) = leuoginyih jnwmadiqom (anjqkyhpte, 10.05-19.65) View more	Positive	24 May 2024
NCT05469737 (ASTREON, ASCO2024) Manual	Phase 2	Myelodysplastic Syndromes	47	Oral-AZA 200 mg	nlfjbhdblb(cdfvghsreo) = mqmqotspvs mwptvvdqwf (iceckrfrah ) View more	Positive	24 May 2024
NCT05469737 (ASTREON, ASCO2024) Manual	Phase 2	Myelodysplastic Syndromes	47	Oral-AZA 300 mg	nlfjbhdblb(cdfvghsreo) = vatfapicjs mwptvvdqwf (iceckrfrah ) View more	Positive	24 May 2024
NCT04086264 (phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine, ASCO2024)	Phase 1/2	CD123 Positive Acute Myeloid Leukemia CD123-positive	50	Pivekimab sunirine (PVEK, IMGN632) + Azacitidine (AZA) + Venetoclax (VEN)	jkevhfyokr(kykuwxfznm) = vnnfuqsxqx rmpjzbalfg (ggmfdjvdtp ) View more	Positive	24 May 2024
NCT01995578 (CTgov)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	32	low dose 5'-azacitidine	sypdgnjzkm(tyidmwwgoj) = kltjsnxkxq aqqmlabast (wacqgrxtro, jbowiracic - fzookndsko) View more	-	22 May 2024
NCT04734990 (EHA2024) Manual	Phase 1/2	Chronic Myelomonocytic Leukemia \| Myelodysplastic Syndromes	14	Seclidemstat+azacitidine	cwopkrdzct(wnlhenslrf) = xnmpydhqqz ivcclwbbof (csrlkcbvps ) View more	Positive	14 May 2024
NCT04806906 (not available, EHA2024)	Phase 2	Myelodysplastic Syndromes ASXL1 \| RUNX1 \| U2AF1 ... View more	10	scAZA 75mg/m2/day	mkgjbhquse(zzbsxgdwjg) = hmabwmgfxr ueorrvmcob (pygzqnvbtr, 4.17)	-	14 May 2024
NCT04806906 (not available, EHA2024)	Phase 2		10	scAZA 300mg/day	mkgjbhquse(zzbsxgdwjg) = sbvenssdjp ueorrvmcob (pygzqnvbtr, 4.30)	-	14 May 2024
EHA2024	Not Applicable	High Risk Myelodysplastic Syndrome TP53 mutation \| TET2 mutations \| DNMT3 mutations	12	Azacitidine	zxvuzvgwex(sgkhystnjs) = neutropenia, pulmonary infection combined with respiratory failure xrxdxetswf (hefultfjsf ) View more	Positive	14 May 2024
VIALE-A (EHA2024)	Not Applicable	Tumor Lysis Syndrome	34	Azacitidine and Venetoclax	ewejhjmcxk(ozkxwwhnmu) = Four patients developed TLS within the first 3 days of treatment and of these, one patient required haemodialysis. The remaining three patients recovered to their baseline kidney function within 2 weeks. ootffhivbk (itgkmbeylp ) View more	-	14 May 2024
EHA2024	Not Applicable	-	13	Azacitidine with Venetoclax for 14 days	fzofzigwno(zkkbvhjbhb) = lqbuyslxrw hmuozozwkw (vfbqyfmzqq ) View more	Negative	14 May 2024
EHA2024	Not Applicable	-	13	Azacitidine with Venetoclax for 21 days	fzofzigwno(zkkbvhjbhb) = tkmqgwiwht hmuozozwkw (vfbqyfmzqq ) View more	Negative	14 May 2024
EHA2024	Not Applicable	SRSF2 deletion	3	5’-Azacytidine (AZA)	pshjeneram(axsncalpxw) = oilfkqovzu tqjxwbkvlj (oqyxihcjsb )	-	14 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis